Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy
Journal of Molecular Cell Biology · 2024
DOI: 10.1093/jmcb/mjad070 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Molecular Cell Biology, 2024. Verfasst von Fangni Chai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, West China Hospital, Sichuan University.
Abstract (Originalsprache)
As a significant member of the immune checkpoint, programmed cell death 1 ligand 1 (PD-L1) plays a critical role in cancer immune escape and has become an important target for cancer immunotherapy. Clinically approved drugs mainly target the extracellular domain of PD-L1. Recently, the small cytoplasmic domain of PD-L1 has been reported to regulate PD-L1 stability and function through multiple pathways. Therefore, the intracellular domain of PD-L1 and its regulatory pathways could be promising targets for cancer therapy, expanding available strategies for combined immunotherapy. Here, we summarize the emerging roles of the PD-L1 cytoplasmic domain and its regulatory pathways. The conserved motifs, homodimerization, and posttranslational modifications of the PD-L1 cytoplasmic domain have been reported to regulate the membrane anchoring, degradation, nuclear translocation, and glycosylation of PD-L1. This summary provides a comprehensive understanding of the functions of the PD-L1 cytoplasmic domain and evaluates the broad prospects for targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
- Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
ORCID-Profile: Haiyan Ren
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- West China Hospital, Sichuan University
Zitieren
APA
Chai, F., Li, P., Liu, X., Zhou, Z., & Ren, H. (2024). Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy. Journal of Molecular Cell Biology. https://doi.org/10.1093/jmcb/mjad070
Vancouver
Chai F, Li P, Liu X, Zhou Z, Ren H. Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy. Journal of Molecular Cell Biology. 2024. doi:10.1093/jmcb/mjad070
BibTeX
@article{Chai2024,
author = {Chai, Fangni and Li, Pan and Liu, Xin and Zhou, Zhihui and Ren, Haiyan},
title = {Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy},
journal = {Journal of Molecular Cell Biology},
year = {2024},
doi = {10.1093/jmcb/mjad070}
}
EUVIMED